Answers are grounded in this paper and cite their sources.
Citalopram is a selective serotonin (5-HT) reuptake inhibitor (SSRI) developed by H. Lundbeck A/S in Denmark. It is the most selective serotonin antidepressant with proven efficacy, a favourable pharmacokinetic profile and a low potential for interactions with other concomitant medication. The drug has a low incidence of side effects, even when compared to the other SSRIs and good patient compliance and satisfaction is a feature of this drug. These factors make the drug a good choice for depressed patients who require continuation and long-term treatment, as well as for elderly patients.
No takes yet. Share an insight, caveat, or question.
Joubert et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: